Pharvaris
Michiel van Esdonk is currently the Associate Director ADME at Pharvaris and also owns Axiaal Data Analytics and PMX Solutions. With a PhD in Pharmacometrics from Leiden University, Michiel has extensive experience in population PK/PD analyses and developing software applications for drug development. As a former Senior Pharmacometrician at the Centre for Human Drug Research, Michiel provided valuable expertise in early-phase clinical trials. Prior to this, Michiel worked as a Type 1 Diabetes Researcher at The University of Queensland, focusing on glycaemic control. With a strong educational background in Bio-Pharmaceutical Sciences, Michiel is dedicated to advancing pharmacometrics in both research and clinical practice.
This person is not in any offices
Pharvaris
2 followers
Pharvaris is a preclinical stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients for use as an alternative to injected therapies for hereditary angioedema (HAE) and other B2 receptor-mediated indications. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.